Compare VTS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | PHAR |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.0M | 793.4M |
| IPO Year | 2022 | 2020 |
| Metric | VTS | PHAR |
|---|---|---|
| Price | $17.97 | $9.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $21.50 | ★ $34.35 |
| AVG Volume (30 Days) | ★ 375.2K | 16.2K |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | ★ 9.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,989,000.00 | N/A |
| Revenue This Year | $26.85 | $1.92 |
| Revenue Next Year | N/A | $8.85 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $15.00 | $9.11 |
| 52 Week High | $22.91 | $21.34 |
| Indicator | VTS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 43.14 |
| Support Level | $17.33 | $9.62 |
| Resistance Level | $18.61 | $11.60 |
| Average True Range (ATR) | 0.38 | 0.29 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 69.52 | 55.67 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.